News

Mwyngil Therapeutics Announces In-Licensing of GPR75 Modulators and Cell-Surface Discovery Platform from Expert Systems Inc.

DOVER, Del., Nov. 6, 2025 /PRNewswire/ -- Mwyngil Therapeutics Inc., a biopharmaceutical company dedicated to developing first-in-class and best-in-class small-molecule therapies...

NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

ZURICH, Nov. 6, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a biotechnology company advancing transformative therapies for...

error: Content is protected !!